Jaguar Health, Inc.

Good afternoon. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to matters such as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, and product initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information and management's current assumptions, expectations, and projections about future events. While management believes its assumptions, expectations, and projections are reasonable in view of currently available information, you are cautioned not to place under reliance on these forward-looking statements. The company's action results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and risk factors section of the company's Form 10-K for the year 2025. which was filed with the SEC on April 7, 2026 and its other filings with the SEC, which are available on the investor relations section of Jaguar's website. Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events, or otherwise. Additionally, please note that the company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which the company management assesses and operates the business. These non-GAAP financial measures should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for or superior to measures of financial performance in conformity with GAAP. Today's conference is being recorded. At this time, it is now my pleasure to turn the call over to Lisa Conte, Jaguar Health's founder, president, and chief executive officer. Lisa, the floor is yours.

Oh, thank you very much, Paul. Hello, and thank you all for joining our investor webcast today. My name is Lisa Conte, as you heard. I'm the founder, president, and CEO of Jaguar Health and our wholly owned subsidiary, NAPO Pharmaceuticals. I'm also the chairman of our Italian subsidiary, NAPO Therapeutics. As usual, I may use the words Jaguar and NAPO interchangeably when I'm referring to our company. After I speak, our CFO, Carol Lizak, will provide a recap of the financial highlights for the second quarter of 2026. The theme of today's webcast is transformation, near-term catalysts, and sharp strategic focus. As many of you who have followed this company may recall, This past January, January 2026, we completed a transformative transaction, the signing of a U.S. commercial out-license agreement with FuturePAC for Mitessi, the brand name of our FDA-approved tablet formulation of Cofelomer for adults living with HIV, AIDS, and diarrhea, and for the brand name Canalivia CA-1, our conditionally approved formulation of Cofelomer for dogs with chemotherapy-induced diarrhea. We made the strategic decision to outlicense My Tessie to FuturePak first because they had recently acquired Thera Technologies, an HIV-focused commercial company with more than four times the commercial effort of Jaguar in the U.S., including two other HIV-related and relevant products. And secondly, to fulfill our strategic plan to bring in meaningful, non-dilutive dollars to help fund our sharp development focus on our pivotal stage program for our novel proprietary powder for oral solution formulation of crofilomer, so a different product of crofilomer. Same active ingredient, different product, different formulation. for rare intestinal failure indications. Rare meaning we have orphan drug designation for the intestinal failure indications in the United States and Europe. We are now fully a rare disease GI company with 100% of our human development efforts sharply and strategically focused on our rare disease program.

Our ultimate strategy